Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Assembly Biosciences Inc is a biotechnology business based in the US. Assembly Biosciences shares (ASMB) are listed on the NASDAQ and all prices are listed in US Dollars. Assembly Biosciences employs 139 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$3.08|
|52-week range||$3.07 - $16.40|
|50-day moving average||$3.29|
|200-day moving average||$3.74|
|Wall St. target price||$9.71|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.43|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-21)||-4.64%|
|1 month (2021-09-28)||-11.75%|
|3 months (2021-07-28)||-13.97%|
|6 months (2021-04-28)||-29.68%|
|1 year (2020-10-27)||-79.20%|
|2 years (2019-10-25)||-79.68%|
|3 years (2018-10-26)||21.98|
|5 years (2016-10-27)||13.96|
|Revenue TTM||$35.6 million|
|Gross profit TTM||$-22,232,000|
|Return on assets TTM||-21.15%|
|Return on equity TTM||-37.51%|
|Market capitalisation||$140.8 million|
TTM: trailing 12 months
There are currently 1.5 million Assembly Biosciences shares held short by investors – that's known as Assembly Biosciences's "short interest". This figure is 8.1% down from 1.6 million last month.
There are a few different ways that this level of interest in shorting Assembly Biosciences shares can be evaluated.
Assembly Biosciences's "short interest ratio" (SIR) is the quantity of Assembly Biosciences shares currently shorted divided by the average quantity of Assembly Biosciences shares traded daily (recently around 849882.45614035). Assembly Biosciences's SIR currently stands at 1.71. In other words for every 100,000 Assembly Biosciences shares traded daily on the market, roughly 1710 shares are currently held short.
However Assembly Biosciences's short interest can also be evaluated against the total number of Assembly Biosciences shares, or, against the total number of tradable Assembly Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Assembly Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Assembly Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0328% of the tradable shares (for every 100,000 tradable Assembly Biosciences shares, roughly 33 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Assembly Biosciences.
Find out more about how you can short Assembly Biosciences stock.
We're not expecting Assembly Biosciences to pay a dividend over the next 12 months.
Assembly Biosciences's shares were split on a 1:5 basis on 13 July 2014. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Assembly Biosciences shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Assembly Biosciences shares which in turn could have impacted Assembly Biosciences's share price.
Over the last 12 months, Assembly Biosciences's shares have ranged in value from as little as $3.07 up to $16.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Assembly Biosciences's is 0.4021. This would suggest that Assembly Biosciences's shares are less volatile than average (for this exchange).
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd. ; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. It also has a clinical collaboration agreement with Antios Therapeutics, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.